We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Studies
Clc3.0
Colchicine Research
Too few graded studies
363 peer-reviewed studies
What the evidence says
Too few graded studies
Colchicine doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 1974–2026.
Based on 362 studies · 88 meta-analyses · 225 RCTs
Confidence
High confidence
By outcome
Cardiovascular eventsLow-dose colchicine reduced major cardiovascular events in coronary disease and after MI in randomized trials · Months to years
Too few graded studies134 studies
Inflammation / inflammagingReduced cardiovascular events in coronary disease in the LoDoCo and COLCOT trials, an anti-inflammatory drug effect. Prescription drug with a narrow safety margin and many interactions · Weeks
Too few graded studies22 studies
Safety profile
Mostly mechanism / observational16 studies
Active research area
173 studies in the last 5 years · Latest meta-analysis: 2026
197420002026
1Meta-Analysis2026
In plain English: Because data were limited and clinically heterogeneous, the findings should not be interpreted as evidence favoring a specific drug class, dose, route, or timing.
Ling H, Yu Z, Shu D. · Pakistan journal of pharmaceutical sciences (2026)
Results Nine RCTs involving 800 patients were included.
Conclusion Recent RCT evidence suggests that perioperative anti-inflammatory interventions can attenuate early inflammatory responses and improve short-term pain and recovery after hip and shoulder arthroplasty.
Because data were limited and clinically heterogeneous, the findings should not be interpreted as evidence favoring a specific drug class, dose, route, or timing.